Navigation Menu

About Us

Harnessing the regenerative power of the human body to develop transformative medicines for CNS disorders

Photo of a lab worker

Our Mission

Our mission is to improve life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.

CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease.  Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.

Leadership Team

Heather SmithAdvisor Will StrattonVice President, Corporate Development and Strategy Gudarz Davar, M.D.Executive Vice President, Head of Research and Development Betsy VaughnVice President, Talent and Culture Jason Harris, Ph.D.Vice President, Research John BorkholderGeneral Counsel and Senior Vice President, Administration Keith LendenSenior Advisor Kevin FinneyChairman, President and CEO

Board of Directors

Uwe Schoenbeck, Ph.D.Venture Partner, Canaan Partners Bonnie van Wilgenburg, Ph.D.Principal, Monograph Capital Philip DeSouza, M.D.Venture Partner, Newpath Partners Thomas Cahill, M.D., Ph.D.Founder and Managing Partner, Newpath Partners Scott GiacobelloChief Financial Officer, Aadi Bioscience, Inc. Timothy AndersonManaging Director, Blue Owl Capital Ben Cravatt, Ph.D.Professor and Gilula Chair of Chemical Biology, the Scripps Research Institute Kristina BurowManaging Director, ARCH Venture Partners Kevin FinneyChairman, President and CEO

Scientific Advisors

Dan Iosifescu, M.D.Professor of Psychiatry, NYU Grossman School of Medicine, Director of Clinical Research Nathan Kline Institute for Psychiatric Research Ben Cravatt, Ph.D.Professor and Gilula Chair of Chemical Biology, the Scripps Research Institute Ellis F. Unger, M.D.Principal Drug Regulatory Expert, Hyman, Phelps & McNamara, P.C. Robert Conley, M.D.Adjunct Professor of Psychiatry and Pharmacy Science at the University of Maryland School of Medicine and a Senior Vice President at Eleusis Ltd. Edmund Harrigan, M.D.Principal, Harrigan Consulting, Inc. Maurizio Fava, M.D.Psychiatrist-In-Chief, Vice Chair, the MGH Executive Committee on Research Bruce Cree, M.D., Ph.D., M.A.S.Neurologist and Clinical Research Director at the UCSF Multiple Sclerosis Center Tom Scanlan, Ph.D.Professor of Physiology and Pharmacology, Oregon Health & Science University

Investors

Logo for Alexandria Venture Investments
Logo for Arch Ventures
Logo for Biogen
Logo for Bristo Meyers Squibb
Logo for BVF Partners
Logo for GT Healthcare
Logo for Invus
Logo for Pfizer
Logo for Samsara Biocapital
Logo for Section 32

Our Science

Our Science